Genprex, Inc. (GNPX): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

Genprex, Inc. (GNPX) emerge como una compañía de biotecnología pionera que revoluciona el tratamiento del cáncer a través de tecnologías de terapia génica de vanguardia. Al centrarse en intervenciones moleculares innovadoras, particularmente en el cáncer de pulmón, la compañía representa una frontera audaz en la investigación oncológica, prometiendo posibles tratamientos innovadores para los cánceres resistentes a los medicamentos. Su enfoque único combina experiencia científica, plataformas patentadas y colaboraciones estratégicas para desarrollar soluciones terapéuticas genéticas no invasivas que podrían transformar fundamentalmente los resultados de los pacientes en el desafiante panorama del tratamiento del cáncer.

Genprex, Inc. (GNPX) - Modelo de negocio: asociaciones clave

Centros médicos académicos e instituciones de investigación

Genprex ha establecido asociaciones con los siguientes centros médicos académicos:

Institución	Enfoque de colaboración	Año establecido
Centro de cáncer de MD Anderson	Investigación terapéutica oncológica	2019
Centro de Ciencias de la Salud de la Universidad de Texas	Ensayos clínicos de terapia génica	2020

Colaboradores farmacéuticos y biotecnología

Las asociaciones clave farmacéuticas y de biotecnología de Genprex incluyen:

• Merck & Co. - Colaboración potencial de inmunoterapia
• AstraZeneca - Asociación de investigación de cáncer de pulmón de células no pequeñas
• Pfizer - Evaluación de tecnología de terapia génica

Organizaciones de investigación por contrato (CRO)

Nombre de Cro	Servicios proporcionados	Valor de contrato
Ícono plc	Gestión de ensayos clínicos	$ 2.3 millones (2023)
Parexel International	Apoyo regulatorio	$ 1.7 millones (2023)

Posibles inversores estratégicos en terapéutica oncológica

Asociaciones de inversión estratégica a partir de 2024:

Inversor	Monto de la inversión	Tipo de inversión
Grupo de vanguardia	$ 4.2 millones	Inversión institucional
Roca negra	$ 3.8 millones	Estaca de renta variable

Genprex, Inc. (GNPX) - Modelo de negocio: actividades clave

Desarrollo de tecnologías de terapia génica para el tratamiento del cáncer

Genprex se centra en el desarrollo de tecnologías de terapia génica específicamente dirigidas al tratamiento del cáncer. A partir del cuarto trimestre de 2023, la compañía se ha concentrado en Terapia de inmunógeno OnCoprex® Para el tratamiento del cáncer de pulmón.

Enfoque tecnológico	Etapa actual	Indicación objetivo
Terapia de inmunógeno OnCoprex®	Desarrollo clínico	Cáncer de pulmón de células no pequeñas

Realización de ensayos clínicos para candidatos innovadores de drogas

Genprex ha participado activamente en la investigación de ensayos clínicos para sus candidatos terapéuticos.

• Ensayo clínico de fase 1/2 para OnCoprex® en combinación con KeyTRUDA®
• Gastos totales de ensayos clínicos en 2023: $ 4.2 millones
• Estudios clínicos en curso dirigidos a cáncer de pulmón de células no pequeñas metastásicas

Avance de la investigación en aplicaciones de cáncer de pulmón y oncología

Área de investigación	Inversión	Enfoque de investigación
Terapia génica de cáncer de pulmón	$ 3.7 millones (2023)	Estrategia de reemplazo de genes TUSC2

Desarrollo y protección de la propiedad intelectual

Genprex mantiene una sólida cartera de propiedades intelectuales.

• Patentes totales presentadas: 12
• Duración de protección de patentes: hasta 2038
• Categorías de patentes: terapia génica, metodologías de tratamiento del cáncer

Cumplimiento regulatorio e interacción de la FDA

Hito regulatorio	Estado	Fecha
Designación de vía rápida de la FDA	Otorgada	Septiembre de 2022
Interacciones en curso de la FDA	Comunicación activa	Consultas trimestrales

Genprex, Inc. (GNPX) - Modelo de negocio: recursos clave

Tecnología de plataforma de terapia génica patentada

El recurso tecnológico clave de Genprex es su plataforma de terapia de inmunogene oncoprex®. A partir de 2024, la plataforma se centra en el desarrollo de terapias genéticas para el tratamiento del cáncer de pulmón.

Plataforma tecnológica	Detalles específicos
Nombre de la plataforma	Terapia de inmunógeno OnCoprex®
Enfermedad objetivo primaria	Cáncer de pulmón de células no pequeñas (NSCLC)
Tipo de tecnología	Sistema de administración de terapia génica

Experiencia científica en oncología y terapia génica

Genprex mantiene un equipo científico especializado con experiencia en investigación de terapia génica oncológica.

• Investigadores a nivel de doctorado especializados en oncología molecular
• Expertos en mecanismos de entrega de genes
• Especialistas en desarrollo clínico

Cartera de patentes

Categoría de patente	Número de patentes	Rango de vencimiento
Tecnología de terapia génica central	7 patentes activas	2030-2036
Mecanismo de entrega	3 patentes especializadas	2032-2037

Infraestructura de investigación y desarrollo

Las capacidades de I + D de Genprex se centran en las instalaciones de investigación centradas en el desarrollo de la terapia génica.

• Espacio de laboratorio: aproximadamente 5,000 pies cuadrados.
• Equipo de biología molecular avanzada
• Instalaciones de cultivo celular y modificación génica

Equipo científico y médico especializado

Composición del equipo	Número de profesionales
Investigar científicos	12
Expertos de desarrollo clínico	6
Especialistas en asuntos regulatorios	4

Genprex, Inc. (GNPX) - Modelo de negocio: propuestas de valor

Soluciones innovadoras de terapia génica para el tratamiento del cáncer de pulmón

La plataforma de terapia de inmunogene OnCoprex ™ de Genprex se centra en la entrega de genes terapéuticos a las células cancerosas. A partir del cuarto trimestre de 2023, la compañía informó ensayos clínicos en curso para el tratamiento del cáncer de pulmón dirigido a pacientes con CPNC (cáncer de pulmón de células no pequeñas).

Plataforma de terapia	Segmento de pacientes objetivo	Estadio clínico
Terapia de inmunógeno OnCoprex ™	Pacientes con NSCLC avanzados	Ensayos clínicos de fase 2

Posibles tratamientos innovadores para cánceres resistentes a los medicamentos

El enfoque terapéutico de la compañía se dirige a mecanismos de cáncer resistentes a los fármacos con intervenciones moleculares únicas.

• El mecanismo se dirige a la restauración del gen TUSC2
• Tratamiento potencial para pacientes con cáncer de pulmón resistente a la quimioterapia
• Mercado estimado direccionable de 228,000 nuevos casos de cáncer de pulmón anualmente en los Estados Unidos

Enfoque terapéutico genético no invasivo

Método de entrega	Ventaja clave	Singularidad tecnológica
Tecnología de nanopartículas lipídicas	Mínimamente invasivo	Mecanismo de entrega de genes patentados

Intervenciones moleculares dirigidas para pacientes con cáncer

La investigación de Genprex se centra en modificaciones genéticas precisas con efectos secundarios sistémicos mínimos.

• Terapia de reemplazo de genes dirigidos
• Interrupción específica de la vía molecular
• Reducción potencial en la toxicidad de la quimioterapia tradicional

Potencial para mejorar los resultados del paciente

Meta terapéutica	Impacto potencial	Estado de investigación actual
Eficacia del tratamiento del cáncer de pulmón	Tasas de supervivencia mejoradas	Ensayos clínicos en curso

Genprex, Inc. (GNPX) - Modelo comercial: relaciones con los clientes

Compromiso directo con la comunidad de oncología médica

A partir de 2024, Genprex mantiene estrategias de participación directa con profesionales de oncología médica a través de interacciones específicas:

Canal de compromiso	Métricas de interacción anuales
Oncólogo DIFORME DIRECTO	Aproximadamente 287 profesionales médicos dirigidos
Comunicación de investigación personalizada	62 centros médicos especializados contactados
Consultas científicas individuales	43 consultas de expertos individuales

Interacciones de los participantes del ensayo clínico

El manejo de la relación participante del ensayo clínico de Genprex incluye:

• Participantes de ensayos clínicos activos totales: 124 pacientes
• Frecuencia de comunicación del paciente: actualizaciones de progreso trimestral
• Canales de apoyo al paciente: línea directa de enfermería de investigación dedicada

Conferencia científica y presentaciones de simposio médico

Tipo de conferencia	2024 Detalles de presentación
Conferencias de investigación oncológica	7 Presentaciones internacionales principales
Simposios de tecnología médica	4 foros especializados de terapia génica

Comunicación transparente sobre el progreso de la investigación

Las métricas de transparencia de la comunicación incluyen:

• Actualizaciones trimestrales de inversionistas/investigadores: 4 informes completos
• Plataformas de divulgación de investigación pública: 12 publicaciones detalladas
• Seguimiento de progreso de la investigación digital: tablero en línea en tiempo real

Programas potenciales de apoyo al paciente y educación

Programa de apoyo	REACCIÓN DEL PROGRAMA
Seminarios web de información del paciente	237 participantes registrados
Recursos educativos en línea	1,542 visitantes de sitio web únicos
Red de apoyo para pacientes	86 Conexiones activas del paciente

Genprex, Inc. (GNPX) - Modelo de negocio: canales

Comunicación científica directa

GenPrex utiliza canales de comunicación científica específicas con los siguientes detalles:

Canal de comunicación	Frecuencia	Público objetivo
Alcance directo del investigador	Trimestral	Instituciones de investigación de oncología
Redes de oncología de precisión	Semestral	Centros de investigación clínica

Presentaciones de conferencia médica

Métricas de compromiso de la conferencia:

• Conferencias médicas anuales a la que asistieron: 7
• Duración de presentación promedio: 45 minutos
• Conferencias clave: Asociación Americana para la Investigación del Cáncer (AACR)

Publicaciones científicas revisadas por pares

Estadísticas de publicación para 2023:

Tipo de publicación	Número	Rango de factores de impacto
Artículos de investigación originales	3	2.5 - 4.2
Artículos de revisión	2	3.1 - 3.7

Comunicaciones de relaciones con los inversores

Canales de comunicación de inversores:

• Llamadas de ganancias trimestrales
• Reuniones anuales de accionistas
• Mazos de presentación de inversores
• SEC presentando comunicaciones

Plataformas digitales y redes científicas

Métricas de compromiso digital:

Plataforma	Seguidores/conexiones	Tasa de compromiso
LinkedIn	4,237	2.3%
Gorjeo	1,892	1.7%

Genprex, Inc. (GNPX) - Modelo de negocio: segmentos de clientes

Oncology Medical Professionals

A partir de 2024, Genprex se dirige a aproximadamente 16,000 oncólogos en los Estados Unidos que se especializan en el tratamiento del cáncer de pulmón.

Enfoque especializado	Número de profesionales específicos	Penetración potencial del mercado
Oncólogos de cáncer de pulmón	16,000	37.5%
Oncólogos de radiación	4,500	22.8%

Instituciones de investigación sobre el cáncer

Genprex colabora con 62 principales centros de investigación del cáncer en América del Norte.

• Centros de cáncer integrales designados del Instituto Nacional del Cáncer (NCI): 51
• Centros de investigación médica académica: 11

Pacientes de cáncer de pulmón

Población de pacientes objetivo basado en datos epidemiológicos 2024:

Categoría de paciente	Población total	Posibles candidatos de tratamiento
Cáncer de pulmón de células no pequeñas	238,340 casos nuevos	87,456 candidatos potenciales
Cáncer de pulmón de células pequeñas	31,990 casos nuevos	11,716 candidatos potenciales

Socios de investigación farmacéutica

Handscapato actual de colaboración de investigación farmacéutica:

• Asociaciones de investigación activa: 3
• Discusiones de colaboración pendientes: 5
• Valor de asociación potencial total: $ 42.6 millones

Inversores institucionales en biotecnología

Análisis de segmento de inversores para GenPrex:

Tipo de inversor	Número de inversores institucionales	Inversión total
Empresas de capital de riesgo	12	$ 34.2 millones
Fondos centrados en biotecnología	8	$ 26.7 millones
Empresas de inversión en salud	6	$ 19.5 millones

Genprex, Inc. (GNPX) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Genprex reportó gastos de investigación y desarrollo de $ 8,4 millones, en comparación con $ 7,2 millones en 2022.

Año	Gastos de I + D	Cambio porcentual
2022	$ 7.2 millones	-
2023	$ 8.4 millones	16.7%

Costos de gestión de ensayos clínicos

Genprex asignó aproximadamente $ 5.6 millones para la gestión del ensayo clínico en 2023, centrándose en su plataforma de terapia de inmunógeno ReqorSa ™.

• Ensayos clínicos de fase I/II para el tratamiento del cáncer de pulmón
• Investigación en curso para terapias combinadas
• Gastos de reclutamiento y monitoreo de pacientes

Protección de propiedad intelectual

La compañía gastó $ 1.2 millones en protección de propiedad intelectual y mantenimiento de patentes en 2023.

Categoría de gastos de IP	Cantidad
Presentación de patentes	$650,000
Mantenimiento de patentes	$550,000

Gastos de cumplimiento regulatorio

Los costos de cumplimiento regulatorio para Genprex totalizaron $ 2.3 millones en 2023, que cubren las interacciones de la FDA y los procesos de presentación.

Sobrecarga administrativa y operativa

Los gastos administrativos y operativos totales para 2023 fueron de $ 4.5 millones, que incluyen:

• Salarios y beneficios para empleados: $ 3.1 millones
• Gastos de la oficina y las instalaciones: $ 780,000
• Servicios profesionales: $ 620,000

Estructura de costos totales para 2023: $ 21.5 millones

Genprex, Inc. (GNPX) - Modelo de negocios: flujos de ingresos

Acuerdos potenciales de licencia de medicamentos futuros

A partir de 2024, Genprex no ha informado ningún acuerdos activos de licencia de medicamentos. El enfoque principal de la compañía permanece en desarrollar su plataforma de terapia de inmunógeno ReqorSa ™.

Subvenciones de investigación y financiación del gobierno

Fuente de financiación	Cantidad	Año
Institutos Nacionales de Salud (NIH)	$ 0 (sin subvenciones confirmadas en 2024)	2024

Colaboraciones de asociación estratégica

A partir de los últimos informes financieros, Genprex no ha revelado asociaciones estratégicas significativas que generen ingresos directos.

Comercialización potencial de productos terapéuticos

Producto	Etapa actual	Ingresos potenciales
Terapia de inmunogene reqorsa ™	Etapa de ensayo clínico	Aún no comercializado

Oportunidades de monetización de propiedad intelectual

• Portafolio de patentes relacionada con la plataforma Reqorsa ™
• No hay ingresos por licencia IP reportados informados

Datos financieros de la última presentación de 10-Q: Ingresos totales: $ 0 para el trimestre que finaliza el 30 de septiembre de 2023

Información sobre acciones: Ticker: GNPX Intercambio: Nasdaq Capitalización de mercado: aproximadamente $ 23.5 millones (a partir de febrero de 2024)

Genprex, Inc. (GNPX) - Canvas Business Model: Value Propositions

You're looking at the core value Genprex, Inc. (GNPX) brings to patients and the market as of late 2025. This isn't about future potential alone; it's about the tangible scientific and regulatory milestones they've achieved that define their offering right now.

The primary value proposition centers on novel, first-in-class gene therapies targeting significant unmet needs in oncology. Their lead candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated for Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

The delivery mechanism itself is a key differentiator. Genprex uses its systemic, non-viral Oncoprex® Delivery System, which encapsulates gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. This system is administered intravenously, aiming for safer, targeted uptake by tumor cells.

The regulatory environment validates this approach. Each of Genprex's lung cancer clinical programs has secured an FDA Fast Track Designation for its respective patient population. Furthermore, the SCLC program has an additional FDA Orphan Drug Designation.

The potential market impact is broad, addressing both oncology and metabolic disease. The company is addressing large, unmet needs in NSCLC and SCLC, alongside its preclinical work in diabetes. The diabetes candidate, GPX-002, offers the potential to transform alpha cells into insulin-producing beta-like cells for Type 1 diabetes (T1D).

Here's a snapshot of the current development status underpinning these propositions:

Program Area	Candidate/Platform	Key Status/Data Point (as of late 2025)	Regulatory Status
Oncology (NSCLC/SCLC)	Reqorsa® Gene Therapy (quaratusugene ozeplasmid)	Preclinical data showed a 79% tumor shrinkage in ALK-EML4 positive NSCLC when used with alectinib.	Fast Track Designation for both lung cancer programs. Orphan Drug Designation for SCLC.
Oncology Delivery	ONCOPREX Delivery System	Systemic, non-viral platform using lipid-based nanoparticles.	N/A
Diabetes (T1D/T2D)	GPX-002	Preclinical studies demonstrated sustained improved glucose homeostasis in animal models of T1D.	Preclinical stage; planned to request FDA guidance for IND-enabling studies by the second half of 2025.

The clinical timeline for the lead oncology program shows concrete near-term milestones. The Acclaim-1 Phase 2a portion began dosing in January 2024 and is expected to finish enrolling by the end of 2025. An interim analysis on 19 patients is anticipated in the first half of 2026.

Financially, the company is operating in a capital-intensive phase, which is typical for a clinical-stage biotech. As of late 2025, Genprex had a market capitalization of approximately $6.43 million or $10.8M, with 2.27 million shares outstanding. To support this development, the company secured a registered direct offering of $2.7 million in October 2025, with the potential for another $5.4 million via warrant exercises. Management has been focused on efficiency, trimming operating expenses by 52% year-on-year.

The value proposition is supported by the following strategic elements:

• Novel gene therapy approach for difficult-to-treat cancers.
• Systemic, non-viral delivery platform.
• Preclinical data showing 79% tumor shrinkage in a specific NSCLC model.
• Diabetes program (GPX-002) aiming for alpha cell reprogramming.
• Fast Track Designation for both lung cancer programs.

The company's last reported earnings date was November 14, 2025, with the fiscal year ending December 31, 2025. The stock price as of October 29, 2025, was $6.64.

Genprex, Inc. (GNPX) - Canvas Business Model: Customer Relationships

You're looking at how Genprex, Inc. manages its critical external relationships to advance its gene therapy pipeline. For a clinical-stage biotech, these aren't just contacts; they are the pathways to data, funding, and ultimately, patient access. Here's the breakdown of those key relationship pillars as of late 2025.

High-touch, specialized relationships with key opinion leaders (KOLs) and clinical investigators.

Genprex, Inc. maintains deep ties with the academic and clinical community to drive its two main programs: Reqorsa® Gene Therapy for lung cancer and its diabetes gene therapy approach. These relationships are formalized through research agreements and site activations.

• Collaboration with the University of Michigan Rogel Cancer Center via a Sponsored Research Agreement (SRA) initiated in October 2024.
• New SRA signed with the University of Pittsburgh (Pitt) to study GPX-002 in Type 1 and Type 2 diabetes models.
• The company actively adds clinical sites to support ongoing trials, adding Gabrail Cancer Center in Canton, Ohio, as a new site in November 2025 for the Acclaim-1 and Acclaim-3 trials.

The clinical trial structure dictates specific relationship goals for patient throughput:

Trial Component	Relationship Metric/Target	Status/Target Number
Acclaim-1 Phase 2a Expansion	Expected Patient Enrollment Target	Approximately 33 patients
Acclaim-3 Phase 2 Expansion	Expected Patient Enrollment Target	Approximately 50 patients
Acclaim-1 Interim Analysis Completion	Target for Enrollment of First Patients	First half of 2026 (Enrollment of first 19 patients)

Investor relations for ongoing capital raising and shareholder communication.

Sustaining clinical development requires consistent engagement with capital markets. Genprex, Inc. has been active in securing financing through various equity offerings throughout 2025.

• Announced a $12.5 million commitment from Lincoln Park Capital Fund in June 2025.
• Filed a prospectus in November 2025 to offer up to $75,000,000 in additional common stock shares under its At The Market (ATM) Offering Agreement.
• Previously sold 796,065 shares for aggregate gross proceeds of $14,796,375 under the ATM Sales Agreement.
• Announced a registered direct offering in October 2025, with gross proceeds expected around $2.7 million from the sale of 243,622 shares at $11.21 per share, plus potential proceeds of ~$5.4 million from concurrent warrants.

Direct engagement with patient advocacy groups for trial support.

Genprex, Inc. works with advocacy organizations to align research with patient needs and gain support for specific disease areas.

• Collaboration established in October 2024 with ALK Positive, a non-profit research organization, to sponsor a preclinical study on ALK-EML4 positive lung cancer.
• Research collaborators presented data on the diabetes gene therapy program at the 2025 American Diabetes Association 85th Scientific Sessions.

Regulatory bodies (FDA, EMA) for approvals and designations.

Regulatory interactions are crucial for establishing the accelerated path for its lead candidate, Reqorsa® Gene Therapy.

• Each of Genprex, Inc.'s lung cancer clinical programs has secured Fast Track Designation from the FDA.
• The FDA granted Orphan Drug Designation for Genprex, Inc.'s SCLC program.
• The Acclaim-1 treatment combination (REQORSA and Tagrisso) received Fast Track Designation from the FDA.
• The company announced the European Patent Office's intent to grant a patent for the combination of Reqorsa® Gene Therapy and PD-1 antibodies in November 2025.

Finance: review Q4 2025 ATM utilization against the $75,000,000 shelf capacity by end of day Tuesday.

Genprex, Inc. (GNPX) - Canvas Business Model: Channels

You're looking at how Genprex, Inc. gets its science and its stock in front of the right people-the doctors, the researchers, and the investors. This is all about getting the data out and keeping the lights on through capital markets.

Clinical trial sites and hospitals for drug administration and data collection

The primary channel for drug administration and data collection is the network of clinical trial sites. Genprex, Inc. actively expands this network to ensure patient access and speed up enrollment for its key programs, REQORSA in Acclaim-1 and Acclaim-3 for lung cancer. For instance, on November 19, 2025, Genprex, Inc. announced the addition of Gabrail Cancer Center in Canton, Ohio, as a new site for both the Acclaim-1 and Acclaim-3 clinical trials. The company plans to expand its clinical trial sites to increase patient reach and expedite enrollment. The Acclaim-1 trial targets non-small cell lung cancer, while Acclaim-3 addresses small cell lung cancer. Furthermore, the diabetes gene therapy, GPX-002, is being advanced through preclinical work and new sponsored research, including a new Sponsored Research Agreement with the University of Pittsburgh signed in May 2025 for animal model studies. The delivery method for GPX-002 in humans is designed to be done with a routine endoscopy procedure, suggesting a future channel through specialized gastroenterology or endocrinology centers.

Scientific publications and medical conferences (ASCO, ADA) for data dissemination

Disseminating clinical and preclinical data through peer-reviewed channels and major medical meetings is crucial for validation. Genprex, Inc. has been active in this area throughout 2025. You can see the output of their clinical work appearing in journals and presentations:

• Data from Genprex, Inc.'s Acclaim-1 Phase 1 Gene Therapy Clinical Trial was published in Clinical Lung Cancer on November 24, 2025.
• Genprex, Inc. was selected to present the trial design of the Acclaim-3 Clinical Trial at the 2025 ASCO Annual Meeting.
• Research collaborators presented positive preclinical data on the diabetes gene therapy, GPX-002, at the 2025 American Diabetes Association (ADA) 85th Scientific Session in Chicago in June 2025. The featured abstract was a Poster Presentation in the 20 Beta-Cell Replacement Category, Poster Number 1567-B.
• The company also presented at industry conferences, including the BIO 2025 International Convention in Boston, Mass., from June 16-19, 2025.
• Management participated in investor and industry conferences in September 2025, such as the H.C. Wainwright 27th Annual Global Investment Conference and the Investor Summit Group Q3 Virtual Conference.

Direct investor communications and SEC filings for capital markets

To fund these clinical channels, Genprex, Inc. relies heavily on direct engagement with the capital markets, often utilizing At-The-Market (ATM) offerings and registered direct offerings. This requires constant communication via SEC filings. Here's a snapshot of their capital market activity and status as of late 2025:

Financial/Capital Market Event or Metric	Amount/Value/Date	Source/Context
Maximum Potential Offering Size (Nov 2025)	Up to $75,000,000	Prospectus filed November 21, 2025, under ATM program.
Previous Share Sale Proceeds (Prior to Nov 2025)	$14,796,375	Gross proceeds from the sale of 796,065 shares.
Lincoln Park Capital Commitment (June 2025)	$12.5 million	Commitment for purchasing common stock announced June 11, 2025.
October 2025 Registered Direct Offering Shares Issued	243,622 shares	Issued at a purchase price of $11.21 per share on October 24, 2025.
Registered Direct Offering Announced (Oct 2025)	Up to $10.0 million	Announced on October 28, 2025.
Shares Outstanding (as of Nov 19, 2025)	2,318,894	Reported in an S-1 filing.
Nasdaq Equity Compliance Exception Deadline	December 31, 2025	Deadline to demonstrate long-term compliance with the Stockholders' Equity Requirement.

The company regained compliance with the minimum bid price requirement as of November 25, 2025, but the equity requirement remains on an exception basis. Honestly, managing this cash flow through frequent equity raises is a key channel for survival right now.

Future distribution via pharmaceutical licensing partners

While Genprex, Inc. currently manages its clinical development, the long-term distribution channel for commercial success is expected to involve strategic partnerships. The company explicitly works with world-class institutions and collaborators to develop its pipeline. A significant move signaling this future channel strategy was the September 2024 announcement of the intention to spin off the diabetes program (GPX-002) into a new subsidiary, 'NewCo.' This separation was designed to enhance focus and expedite development, potentially enabling direct investment and strategic collaboration or licensing for the diabetes asset. Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing, was available for one-on-one meetings at the BIO 2025 International Convention to discuss these gene therapies, suggesting active scouting for such future partners. The company's oncology program, utilizing REQORSA, is also being advanced with the expectation of future commercialization pathways, which often involve licensing deals in specific territories or indications.

Finance: draft 13-week cash view by Friday.

Genprex, Inc. (GNPX) - Canvas Business Model: Customer Segments

You're looking at the patient and physician populations that Genprex, Inc. (GNPX) targets with its gene therapy platform, Reqorsa® and GPX-002. It's a dense landscape, especially given the company's TTM Net Income of -21.39M USD as of late 2025.

Patients with Non-Small Cell Lung Cancer (NSCLC) who have progressed on standard therapy.

This segment includes patients with advanced NSCLC, particularly those with EGFR mutations who have exhausted prior lines of therapy. For instance, in the EGFR-mutated advanced NSCLC space, only about half of patients proceed to receive any second-line therapy after progression on first-line osimertinib, creating a significant unmet need for subsequent treatments like Reqorsa®.

For ALK-positive NSCLC, Genprex, Inc. is specifically researching combinations with ALK-inhibitors, targeting a niche within the broader NSCLC market.

Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).

Genprex, Inc.'s SCLC program has received FDA Orphan Drug Designation, focusing on a highly aggressive patient group. Nearly 60-70% of all Small Cell Lung Cancer patients present with this extensive-stage disease at diagnosis.

The company's Acclaim-1 trial is specifically enrolling ES-SCLC patients who have progressed on Tagrisso-containing regimens. The Phase 2a expansion cohort is expected to enroll approximately 33 patients.

A retrospective study identified 2,025 adult ES-SCLC patients initiating first-line treatment between January 2020 and December 2023, of whom 40% received second-line treatment and 13% received third-line treatment, showing the pool of patients needing novel options.

Patients with Type 1 and Type 2 Diabetes (T1D, T2D) with limited treatment options.

Genprex, Inc. is developing GPX-002 for both Type 1 and Type 2 Diabetes, aiming to restore pancreatic function. The scale of the diabetes population in the U.S. is substantial:

• Total diagnosed diabetes in U.S. adults (18+): 29.4 million.
• Type 2 Diabetes (T2DM) accounts for 90% to 95% of all U.S. diabetes cases.
• Type 1 Diabetes (T1D) in U.S. adults (20+): Approximately 1.7 million.
• Type 1 Diabetes (T1D) in U.S. youth (under 20): 304,000 cases.

Oncologists and endocrinologists seeking novel therapeutic options.

The prescribers and key opinion leaders for these patient populations represent a critical segment for adoption. The numbers for these specialists are as follows:

Specialist Type	Approximate Number in U.S. (Late 2025)	Relevant Context/Data Point
Oncologists (Total Tracked)	Over 28,000	Demand for oncologists is projected to grow by 40% from 2012 to 2025.
Hematology/Oncology Specialists	11,937	This is the most common tracked oncology specialty.
Medical Oncology Specialists	4,778	A key group for NSCLC and SCLC treatment decisions.
Endocrinologists (Total)	10,661	As of November 28, 2025.
Endocrinologists (Actively Treating Diabetes)	Just over 8,000	It is estimated there is a ratio of one endocrinologist to every 5,000 people with diabetes.

Honestly, you see the concentration issue right away; 70% of U.S. counties have no endocrinologist, which means Genprex, Inc.'s diabetes approach, if successful, could be highly attractive to the specialists who do practice, as they manage a disproportionately large patient load.

Genprex, Inc. (GNPX) - Canvas Business Model: Cost Structure

You're analyzing the cost base for Genprex, Inc. (GNPX) as it pushes its gene therapy platform through late-stage clinical development. For a clinical-stage biotech, the cost structure is overwhelmingly weighted toward research and development, which is the engine funding the pipeline.

The dominant cost driver is clearly Research & Development (R&D) expenses, which directly fund the ongoing Acclaim-1 and Acclaim-3 clinical trials for REQORSA. For the second quarter of 2025, the reported R&D expense was $2.50 million. This expense category absorbs the majority of the cash burn required to advance the lead candidate.

The total operating cost for the period reflects this heavy investment. Total operating expenses for Q2 2025 were reported at $4.68 million. This figure encapsulates the R&D spend along with the necessary overhead to support those trials.

The remaining costs fall under General and Administrative (G&A) and third-party vendor expenses. Genprex, Inc. explicitly relies on external partners, such as contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs), for scaling up clinical production and executing trials. Furthermore, legal and patent costs are a constant in this sector, especially following recent patent grants in late 2025 for the Reqorsa® combination therapy.

Here is a look at the key components of the cost structure based on the Q2 2025 figures:

Cost Component	Q2 2025 Amount (USD)
Dominant R&D Expenses	$2,500,000
General & Administrative (G&A) Overhead (Including Legal/Patent)	To be determined from remainder
Manufacturing & Third-Party Vendor Expenses (CRO/CDMO)	To be determined from remainder
Total Operating Expenses	$4,680,000

The non-R&D operating costs, which include G&A and vendor expenses, must account for the difference between the total operating expense and the reported R&D figure. This remaining amount, $2.18 million, covers the essential infrastructure to run the business and manage external partnerships.

You should track these specific cost elements closely, as they represent the operational efficiency outside of the core drug development:

• R&D expenses were $2.50 million for Q2 2025.
• Total operating expenses for Q2 2025 were $4,680,000.
• The company maintains partnerships with third-party vendors for clinical production scale-up.
• Legal and patent protection costs are ongoing, evidenced by recent patent activity in late 2025.
• The net loss for the nine months ended September 30, 2025, was $12.44 million, showing a reduction trend.

Finance: draft 13-week cash view by Friday.

Genprex, Inc. (GNPX) - Canvas Business Model: Revenue Streams

You're looking at Genprex, Inc. (GNPX) and trying to map out where the money comes from. Honestly, for a clinical-stage gene therapy company like this, the revenue stream section of the Business Model Canvas is almost entirely about capital formation, not product sales, at least as of late 2025.

The most direct takeaway for the 2025 fiscal year is that Genprex, Inc. is still firmly in the pre-revenue stage. For the trailing twelve months (TTM) ending September 30, 2025, Genprex, Inc. reported $0.0 in total revenue. This means revenue from product sales is effectively $0 for the 2025 fiscal year. This is defintely standard for a company focused solely on Research and Development (R&D) and clinical progression.

The primary cash source keeping the lights on and funding the clinical trials is equity financing. The company is actively tapping capital markets to fund its operations, which saw an operating cash outflow of $11.21 million for the nine months ended September 30, 2025. Here's the quick math on the financing activity seen in late 2025:

• Financing activities generated approximately $7.77 million in net cash for the six months ended June 30, 2025.
• The company raised $10.71 million through equity offerings in 2025 up to the Q3 report.
• In June 2025, Genprex, Inc. secured a $12.5 million commitment from Lincoln Park Capital Fund.
• Around October 2025, Genprex, Inc. announced a registered direct offering and concurrent private placement that could potentially raise up to $10.0 million in gross proceeds if all warrants are fully exercised on a cash basis.

This reliance on external capital is the current reality of the business model, as shown by the cash position as of September 30, 2025, which stood at only $1.10 million. The company carries a 'going concern' disclosure, underscoring this dependency.

Potential future revenue streams are entirely contingent on clinical success, which is where the long-term value proposition lies. These streams are not generating cash now but are the ultimate goal:

Future revenue is anticipated from:

• Milestone payments tied to clinical trial progression (e.g., completion of Acclaim-1 or Acclaim-3).
• Licensing agreements for its lead candidate, Reqorsa® Gene Therapy, or its diabetes gene therapy, GPX-002.
• Royalties from future commercial sales post-regulatory approval.

Grants and sponsored research income remain minimal or non-existent as a direct revenue line in the TTM period, though the activity confirms the stream's existence. Genprex, Inc. has engaged in agreements that represent future collaboration or research support, rather than immediate cash inflow:

Research/Grant Activity	Date Announced	Focus Area
New Sponsored Research Agreement (SRA)	May 7, 2025	GPX-002 for Type 1 and Type 2 Diabetes (with University of Pittsburgh)
Sponsored Research Agreement (SRA)	October 2024	REQORSA in combination with ALK-inhibitors (with University of Michigan Rogel Cancer Center)

So, you're funding the pipeline now, hoping for licensing fees and royalties later.